Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course vs. standard antibiotics for Gram-positive cocci infective endocarditis
NCT04222257Phase 4Terminated
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in infective endocarditis (IE). Primary endpoint: Composite endpoint of all-cause mortality, unplanned cardiac surgery, symptomatic embolisms and relapses at 6 months. Started Jan 2021; status: terminated.
02
Conditions
infective endocarditis (IE)
Beyond the preview
Go deeper on NCT04222257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222257.